For years, scientists have known that something connects the gut to depression. Studies kept finding the same thread — people with major depressive disorder tended to have different gut microbiome compositions than people without it. One bacterium in particular kept showing up in the data: Morganella morganii. But the connection was always circumstantial. Nobody could explain how a microbe living in your intestine could have anything to do with the way your mind felt.
Now, for the first time, Harvard Medical School researchers have answered that question — at the molecular level.
A new study from the Clardy Lab at Harvard Medical School, published in the Journal of the American Chemical Society, has identified an exact biochemical chain of events that links M. morganii in the gut to inflammation in the body — and from inflammation, to depression. The mechanism involves a common industrial pollutant that most people are exposed to every day, and it suggests that for some individuals, depression may have a root cause that no antidepressant has ever been designed to address.
The Gut–Brain Connection Gets Specific
The concept of a gut–brain axis — the idea that the microbiome influences mental health — has grown steadily over the past decade. It appears in clinical studies, in animal models, in population surveys. But “the gut is linked to depression” is a very different statement from “this specific bacterium, through this specific mechanism, contributes to major depressive disorder in this specific way.”
The Harvard team set out to close that gap.
Their starting point was Morganella morganii — a Gram-negative bacterium that lives in the intestinal tract of humans, sometimes harmlessly, sometimes as an opportunistic pathogen. Earlier research had already produced strong statistical associations between elevated levels of M. morganii in the gut and higher rates of major depressive disorder. The same bacterium had also been linked to inflammatory bowel disease and type 2 diabetes — two conditions known to co-occur with depression at unusually high rates.
The association was compelling. The mechanism was missing.
Using a bioassay-guided fractionation approach — a method that works backward from a biological effect to the molecule responsible for it — the researchers identified the specific molecules that M. morganii produces which are capable of triggering an immune response.
A Pollutant in the Gut — The Missing Link
What they found was unexpected.
M. morganii produces phospholipids — fatty molecules that are a normal part of bacterial cell membranes. Under ordinary circumstances, one of these molecules contains a sugar alcohol at its center. But the Harvard team discovered that when the bacterium is exposed to diethanolamine (DEA) — a common industrial chemical — the DEA can substitute for that sugar alcohol, producing an altered molecule with dramatically different biological properties.
DEA is not exotic. It is found in agricultural products, industrial solvents, and an enormous range of consumer goods — shampoos, soaps, cosmetics, and lubricants. Most people encounter it regularly at low levels without any obvious consequence. But the new study suggests that for individuals who carry M. morganii in their gut, even low-level DEA exposure could be silently contributing to an inflammatory process with real consequences for mental health.
The altered phospholipid molecule that DEA helps create resembles cardiolipin — a lipid that the immune system recognizes as a danger signal, typically associated with damaged cells or bacterial invasion. The body, encountering this molecule, responds as it would to a genuine threat.
It activates immune receptors — specifically TLR1 and TLR2 — and releases a cascade of inflammatory proteins called cytokines. The most significant of these is interleukin-6 (IL-6).
The Role of IL-6: Where Immunity Meets Mental Health
Interleukin-6 has been appearing in depression research for years, but its role has always been difficult to pin down. Elevated IL-6 levels are consistently found in patients with major depressive disorder. Conditions with strong inflammatory components — rheumatoid arthritis, inflammatory bowel disease, type 2 diabetes — all carry significantly elevated rates of depression. Anti-inflammatory treatments have shown modest but real effects on depressive symptoms in some patients.
What the Harvard study now provides is a plausible molecular story connecting all of these dots.
M. morganii is present in the gut. It encounters DEA from environmental exposure. The DEA is incorporated into one of the bacterium’s phospholipid molecules, altering it. The altered molecule activates TLR2/TLR1 immune receptors. The immune system releases IL-6. Chronic IL-6 elevation contributes to the development of major depressive disorder.
As the study’s authors put it, the findings tell a coherent story — from M. morganii at the beginning to depression at the end.
Lead author Sunghee Bang and senior author Jon Clardy, a professor of biological chemistry and molecular pharmacology at Harvard Medical School, noted that the study takes the gut–microbiome–depression link one step further, toward a real understanding of the molecular mechanisms involved.
What Makes This Discovery Different
The significance of this study lies not just in identifying M. morganii as a possible contributor to depression, but in the precision with which the mechanism has now been described.
Previous research established correlation. This study describes causation at the molecular level — a specific molecule, produced through a specific interaction, activating a specific immune pathway, releasing a specific cytokine that is independently associated with the disorder.
That level of specificity matters enormously for what comes next. Because if you know the mechanism, you can potentially interrupt it.
Several potential intervention points now exist on this newly mapped chain. Reducing M. morganii colonization through targeted probiotics or dietary change. Reducing DEA exposure through consumer product reformulation or environmental regulation. Blocking the immune receptors (TLR1/TLR2) that the altered molecule activates. Or targeting IL-6 directly — a strategy already pursued in conditions like rheumatoid arthritis and COVID-19 cytokine storms using drugs like tocilizumab.
The researchers also proposed that DEA itself — now shown to be incorporated into an inflammation-triggering molecule — could potentially serve as a biomarker: a measurable signal in the body that flags elevated risk for depression before clinical symptoms appear.
Implications for How We Think About Depression
One of the broader implications of this study is its support for the idea that major depressive disorder has meaningful connections to autoimmune disease.
Depression is still predominantly treated as a condition of neurotransmitter imbalance — a problem of serotonin, norepinephrine, and dopamine that is addressed with antidepressants targeting those systems. But roughly one-third of patients with major depressive disorder do not respond adequately to these treatments. The so-called “treatment-resistant depression” population represents millions of people worldwide for whom current pharmacology is simply not working.
The Harvard findings suggest that for at least some of these individuals, the underlying driver of depression may not be primarily a neurotransmitter problem at all — it may be an inflammatory one, triggered at the gut level by an interaction between a common microbe and everyday chemical exposure. For these patients, anti-inflammatory approaches or microbiome-targeted interventions might succeed where conventional antidepressants have not.
The researchers acknowledge that much work remains. How common is M. morganii colonization in depressed populations? What proportion of depression cases might involve this contaminant–inflammation route? Does reducing DEA exposure or M. morganii burden actually alleviate symptoms in affected individuals? These questions are now clearly defined targets for follow-up research.
What This Means for You
The immediate practical takeaway is limited — this is not a study that recommends specific actions for people experiencing depression. The mechanisms it describes are real, but the clinical applications are still in development.
What it does offer is a meaningful reframing of where depression comes from — and the emerging recognition that the gut, the immune system, and the external chemical environment are all part of that story. Mental health, it turns out, is not sealed off inside the skull. It is entangled with the microbial ecosystem in the gut and the chemical world we all move through every day.
That understanding, even without immediate treatment implications, is a significant scientific step forward.
Key Facts at a Glance
| Detail | Data |
|---|---|
| Bacterium Studied | Morganella morganii |
| Research Institution | Clardy Lab, Harvard Medical School & Broad Institute |
| Lead Author | Sunghee Bang |
| Senior Author | Jon Clardy, Harvard Medical School |
| Pollutant Involved | Diethanolamine (DEA) |
| Immune Pathway Activated | TLR1 / TLR2 receptors |
| Key Cytokine Released | Interleukin-6 (IL-6) |
| Molecule Type Identified | Unusual phospholipids (DEA-substituted cardiolipin analogues) |
| Condition Linked To | Major Depressive Disorder (MDD) |
| Journal | Journal of the American Chemical Society (JACS) |
| DOI | 10.1021/jacs.4c15158 |
| Featured by Harvard HMS | April 25, 2026 |
Original Journal & Institutional Sources
Peer-Reviewed Paper (Primary Source): Sunghee Bang, Yern-Hyerk Shin, Sung-Moo Park, Lei Deng, R. Thomas Williamson, Daniel B. Graham, Ramnik J. Xavier, Jon Clardy. “Unusual Phospholipids from Morganella morganii Linked to Depression.” Journal of the American Chemical Society, 2025; 147 (4): 2998. 🔗 DOI: 10.1021/jacs.4c15158
Full Text — PubMed Central (Free Access): 🔗 PMC Article: Unusual Phospholipids from Morganella morganii Linked to Depression
Harvard Medical School Official News Release (April 25, 2026): 🔗 Drawing a Line From the Gut Microbiome to Inflammation and Depression — HMS
Harvard Department of Biological Chemistry & Molecular Pharmacology: 🔗 Getting at the how of gut bacteria’s connection to depression — Harvard BCMP
Scienceable.net covers the latest peer-reviewed discoveries in health, neuroscience, and medicine. For more stories like this, visit our Mental Health & Brain section.
